# REDUCING DIAGNOSTIC ERROR

THE EARLY BIRD LOOSES THE DIAGNOSTIC WORM – SCREENING FOR EARLY DISEASE 👚 DIAGNOSTIC ERROR

© 2016 Mark Gusack, M.D.

**MANX Enterprises, Ltd.**®

1. Describe how advances in our capacity to screen for early disease has led to greater frequency and significance of diagnostic error. 2. Explain how societal pressures have forced an increase in false positive diagnosis leading to inappropriate therapy.

3. Discuss how the resulting harm this trend has caused our patients.

### **SITUATION**

Advances in medical science have led to a dramatic increase in our capacity to screen for early disease. The hope is to increase diagnostic certainty thereby reducing morbidity and mortality. However, this new capability to detect earlier stages of disease has led to decreasing reliability of diagnostic criteria resulting in a downward spiral of litigation, legislation, and regulation forcing providers to systematically err on the side of making the diagnosis of disease that is not present.

This has lead to our treating large numbers of patients without disease to avoid malpractice lawsuits, dodge social pressures, and escape hospital sanctions on false negative diagnoses. Considering the risks of therapy, this trend has paradoxically placed large numbers of patients in harm's way despite, and in fact, due to these efforts.

### **PROBLEM**

How do we introduce new more powerful screening tools and continue to:

RISK acc acc Mir dela

UTILITY

Maximize patient safety with correct and timely diagnoses, accurately communicated and acted upon

Minimize discomfort and the pain suffered due to wrong, delayed, or miscommunicated diagnoses

Minimize expenditure of scarce resources through improved cost effective diagnostic processes

### SOLUTION

To significantly reduce diagnostic error that occurs due to screening we need to:

- → Determine an accurate measure of disease prevalence
- → Attempt to establish how disease is distributed in specific patient populations
- ➡ Establish an accurate representation of the natural history of the disease
- Establish more reliable diagnostic criteria for earlier lesions and disease processes
   Develop more reliable diagnostic methodologies to establish diagnostic criteria
- Develop genomic/ribonomic/proteomic screening/diagnostic modalities
- ➡ Educate our clinicians as to the present limitations of early screening
- Educate our patients regarding the limitations of medical science at this juncture


→ Push back against social/regulatory/legal/financial pressures that harm patients

### **IMPLEMENTATION**


The paradox of screening for subclinical disease is so deeply embedded in our healthcare system socially, professionally, and financially that the implementation of the proposed solution will not be simple. Steps that should be considered:


- ➡ Re-design of medical school curricula to emphasize the mathematical background to diagnostics: STATISTICS, EPIDEMIOLOGY, AND LOGIC
- ➡ Re-design of residency training curricula to emphasize the need to develop a view to balance benefits against risks in the screening process
- → Rethink how basic science research is carried out and translated into clinical trials and so screening, diagnosis, and treatment modalities
- ➡ Institute vigorous and exacting validation of journal articles to prevent the implementation of poorly worked out "Science" in medicine


## ILLUSTRATION OF THE EFFECT OF INCREASING SCREENING SENSITIVITY



#### DIAGNOSTIC CHALLENGE BEFORE SCREENING Early Neoplasti Clone Intermediate Neoplastic Clone Neoplastic Clone PATHOLOGY ATYPIA → LG DYSPLASIA HG DYSPLASIA → INVASION GION **→** METS **RADIOLOGY SUSPICIOUS** Easy to Diagnose Hard to Easy to Diagnose Diagnose SMALL NUMBER OF CASES **Small** Number **Large** Number of Cases of Cases **SHORT TIME** LONG LEAD TIME **INTERMEDITATE TIM** THE GREY ZONE However, prior to screening, most lesions coming to clinical attention are late and so easily diagnosed







### COST BENEFIT ANALYSIS

**RISK** 

The benefits of handling high sensitivity screening is significant including but not limited to:


Decreased in false positive diagnoses leading to reduced harm
Shift of diagnostic criteria to be more sensitive further increases this harm

Reduced false positive diagnoses reduces patient anxiety and suffering

improving their quality of life
 More effective use of better designed screening tests leads to reduced waste of scarce resources while improving the benefits accrured

The benefits of pushing this is incalculable!

### CASCADING PARADOX OF SCREENING



### CONCLUSION

- → The paradox of increasing diagnostic error with early screening has introduced confounding influences that reverberate throughout the entire healthcare system from clinical research and therapeutic trials to government regulation.
- → The adverse affect this has on patient safety, quality of care, and cost of health care is substantial.
- → Therefore, a major sea change is necessary in scientific inquiry, medical education, and social behavior before we can begin to significantly:

REDUCE DIAGNOSTIC ERROR IN MEDICINE

### REFERENCES – SELECTED:

- 1. McNeil B.J., Adelstein S.J. Determining the Value of Diagnostic and Screening Tests. The Journal of Nuclear Medicine (1976) 17, 439 448.
- 2. Fox, M.S. On the Diagnosis and Treatment of Breast Cancer. JAMA (1979) 241:5, 489 494.
- 3. Brown G.W. **Keeping Personal Values Out of Predictive Values**. Diagnostic Medicine (1984) Jul-Aug, 39 43.
  4. Black W.C., Welch H.G. **Advances in Diagnostic Imaging and Overestimations of Disease Prevalence and the Benefits of Therapy**. NEJM (1993) 328:17, 1237 1243.
- 5. Tajer C.D. **Therapeutic Trials, Statistical Significance, and Clinical Relevance**. Revista Argentina de Cardiologia (2010) 78:4, 385 390.
- 6. Brito J.P., Morris J.C., Montori V.M. **Thyroid Cancer: Zealous Imaging has Increased Detection and Treatment of Low Risk Tumours**. BMJ (2013) 1 6 doi: 10:1136/bmj.f4706.

  7. Calhoun B.C., Livasy C.A. **Mitigating Overdiagnosis and Overtreatment in Breast Cancer**. Arch Pathol Lab Med (2014) 138, 1428 1431.
- 8. Sangle N.A., et al. **Overdiagnosis of High-grade dysplasia in Barrett's Esophagus**: A Multicenter, International Study. Modern Pathology (2015) 28, 758-765.

  9. Penson D.F. **The Pendulum of Prostate Cancer Screening**. JAMA (2015) 314:19, 2031 2033.
- 10. Loberg M., et al. Benefits and Harms of Mammography Screening. Breast Cancer Research (2015) 17:63, 1 12 doi: 10.1186/s13058-015-0525-z.

  11. Elmore J.G., et al. Variability in Pathologists' Interpretations of Individual Breast Biopsy Slides: A Population Perspective. Ann of Intern Med (2016) 1 7 doi: 10.7326/M15-0964.